Abstract: The present disclosure provides a method for building a finite element model of corneal endothelial cells, including: importing a standard corneal model into finite element pre-processing software, and generating 2D meshes, to obtain a basic mesh model; importing a detailed geometric model of corneal endothelial cells; determining a complete corneal endothelial cell model according to the basic mesh model and the detailed geometric model; and performing calculation according to the complete corneal endothelial cell model. The present disclosure can improve the efficiency and effect of building a finite element model of corneal endothelial cells.

Abstract: In response to poor solubility and permeability of conventional voriconazole eye drops and short retention time thereof at the ocular surface, a preparation method of voriconazole hydrogel and eye drops using the same are provided. The preparation method includes steps of: adding DAPA and sodium hydroxide to deionized water, stirring until completely dissolved to produce a DAPA solution; dropping the DAPA solution into triformylbenzene ethanol solution, and reacting at room temperature; then centrifugating, washing precipitation with ethanol, and freeze-drying in vacuum, so as to obtain a polyaldehyde oligomer; and reacting the polyaldehyde oligomer with AHA to synthesize the voriconazole hydrogel. A preparation method of a topical ocular drug includes: applying a therapeutically effective amount the voriconazole hydrogel, wherein the topical ocular drug is for mechanical injury or fungal keratitis. The present invention improves aqueous solubility, penetration, and ocular surface retention time of VCZ.

Abstract: A sympathetic activation inhibitor and/or an ?1-adrenergic receptor inhibitor in preparing a medicine for treating dry eyes and belonging to the technical field of medicines for treating dry eyes, and a use of a sympathetic activation inhibitor and/or an ?1-adrenergic receptor inhibitor in preparing a medicine for treating or relieving dry eye syndrome. The medicine prepared by the use can antagonize an ?1-adrenergic receptor (including an ?1a-adrenergic receptor) or inhibit sympathetic activation, and can relieve and treat dry eye symptoms.